| ■ 영문 제목 : Adeno Associated Virus Vector Manufacturing Market Size, Share & Trends Analysis Report By Scale Of Operations (Clinical, Commercial), By Method, By Application, By Therapeutic Area, By Region, And Segment Forecasts, 2023 - 2030
|
 | ■ 상품코드 : GRV23MR008
■ 조사/발행회사 : Grand View Research
■ 발행일 : 2023년 2월
■ 페이지수 : 180
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (납기:3일)
■ 조사대상 지역 : 세계
■ 산업 분야 : 의료
|
■ 판매가격 / 옵션
(부가세 10% 별도)
| Single User (1인 열람용) | USD5,950 ⇒환산￦8,032,500 | 견적의뢰/주문/질문 |
| Multi User (5인 열람용) | USD6,950 ⇒환산￦9,382,500 | 견적의뢰/주문/질문 |
| Global/corporate License (기업 열람용) | USD8,950 ⇒환산￦12,082,500 | 견적의뢰/구입/질문 |
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
|
미국 Grand View Research (그랜드뷰리서치)의 본 조사 보고서는 세계의 아데노 수반 바이러스 벡터 제조 시장 규모가 2023년부터 2030년 사이에 CAGR 22.5% 증가하여, 2030년에는 39.5억 달러에 달할 것으로 예상하고 있습니다. 본 조사 자료는 세계의 아데노 수반 바이러스 벡터 제조 시장을 조사대상으로 하여, 조사 방법 및 범위, 개요, 시장 변동/동향/범위, 사업 규모별 (임상, 상업) 분석, 방법별 (인비트로, 인비보) 분석, 용도별 (혈액 질환, 감염증, 유전성 질환, 신경계 질환, 기타) 분석, 치료 영역별 (세포 요법, 유전자 치료, CRO, 백신) 분석, 지역별 (북미, 유럽, 아시아 태평양, 중남미, 중동 및 아프리카) 분석, 경쟁 현황 등의 내용을 수록하고 있습니다. 또한 본 자료는 Roche, Biomarin Pharmaceutical, Oxford BioMedica, WuXi AppTec, YPOSKESI, Sarepta Therapeutics, Pfizer, Audentes Therapeutics 와 같은 기업 정보를 포함하고 있습니다.
・조사 방법 및 범위
・개요
・시장 변동/동향/범위
・세계의 아데노 수반 바이러스 벡터 제조 시장 규모 : 사업 규모별
- 임상용 아데노 수반 바이러스 벡터 제조의 시장 규모
- 상업용 아데노 수반 바이러스 벡터 제조의 시장 규모
・세계의 아데노 수반 바이러스 벡터 제조 시장 규모 : 방법별
- 인비트로 아데노 수반 바이러스 벡터 제조의 시장 규모
- 인비보 아데노 수반 바이러스 벡터 제조의 시장 규모
・세계의 아데노 수반 바이러스 벡터 제조 시장 규모 : 용도별
- 혈액 질환에 사용되는 아데노 수반 바이러스 벡터 제조의 시장 규모
- 감염증에 사용되는 아데노 수반 바이러스 벡터 제조의 시장 규모
- 유전성 질환에 사용되는 아데노 수반 바이러스 벡터 제조의 시장 규모
- 신경계 질환에 사용되는 아데노 수반 바이러스 벡터 제조의 시장 규모
- 기타 용도에 사용되는 아데노 수반 바이러스 벡터 제조의 시장 규모
・세계의 아데노 수반 바이러스 벡터 제조 시장 규모 : 치료 영역별
- 세포 요법에 사용되는 아데노 수반 바이러스 벡터 제조의 시장 규모
- 유전자 치료에 사용되는 아데노 수반 바이러스 벡터 제조의 시장 규모
- CRO에 사용되는 아데노 수반 바이러스 벡터 제조의 시장 규모
- 백신에 사용되는 아데노 수반 바이러스 벡터 제조의 시장 규모
・세계의 아데노 수반 바이러스 벡터 제조 시장 규모 : 지역별
- 북미의 아데노 수반 바이러스 벡터 제조 시장 규모
- 유럽의 아데노 수반 바이러스 벡터 제조 시장 규모
- 아시아 태평양의 아데노 수반 바이러스 벡터 제조 시장 규모
- 중남미의 아데노 수반 바이러스 벡터 제조 시장 규모
- 중동 및 아프리카의 아데노 수반 바이러스 벡터 제조 시장 규모
・경쟁 현황 |
■ 보고서 개요Adeno Associated Virus Vector Manufacturing Market Growth & Trends
The global adeno associated virus vector manufacturing market size is expected to reach USD 3.95 billion by 2030, registering a CAGR of 22.5% over the forecast period, according to a new report by Grand View Research, Inc. This growth is attributed to the increasing prevalence of chronic diseases like cancers, cystic fibrosis, Duchenne muscular dystrophy, retinitis pigmentosa, and many more. AAV vector plays a vital role in the treatment of these diseases. AAV vectors also have a wide range of applications in gene therapy delivery. Companies are engaged in collaborations, mergers, and partnerships for innovative product launches with advancements in R&D.
For instance, in December 2021, Astellas and Dyno Therapeutics entered into a strategic collaboration to develop an NGS-based AAV vector for gene therapy by using Dyno’s CapsidMap platform for cardiac and skeletal muscle. Such initiatives are expected to expand their market presence in the development and production of antibodies, which is likely to support the growth of the market. The COVID-19 pandemic had a positive impact on the industry. As adeno associated virus has vast applications in vaccine manufacturing, various companies were involved in the race to manufacture the vaccine to treat COVID-19. This resulted in a sudden spur in the demand for manufacturing these vectors.
For instance, in September 2021, CEVEC and UCB entered into a strategic agreement for the use of ELEVECTA AAV vector manufacturing technology for R&D and gene therapy applications. As gene therapy involves alterations or modifications in the set of genes, it has raised many ethical issues. As a result, the U.S. government restricted the usage of federal funds for research on germline gene therapy in people. Gene therapy can help save future generations of a family from acquiring a particular genetic disorder. However, it is anticipated to affect the fetus’s development significantly. The high demand for vaccines, gene therapeutics, CGMP drugs, and products to treat & cure acute diseases and the demand for improving patient care also propel the industry growth. Thus, global stakeholders are investing significantly in expanding their production capacities to fulfill the growing demands.
Adeno Associated Virus Vector Manufacturing Market Report Highlights
• By the scale of operations, the commercial segment dominated the industry in 2022. Owing to the increasing R&D investment by companies and demand from vaccine manufacturers
• The neurological diseases therapeutic areasegment captured the largest share in 2022 due to the high prevalence of chronic neurodegenerative diseases and the effectiveness of the adeno associated virus vector-based therapies to treat these disease
• Vaccine is considered a key application segment, which held the largest revenue share in 2022 and is likely to remain dominant throughout the forecast period due to the rising demand for vaccine therapeutics and increasing investments & funds for the production of vaccines
• North America has established a strong regional position. The increasing incidence of cancer and high R&D expenditure is encouraging companies in the region to undertake product development, which drives the regional market
■ 보고서 목차Table of Contents
Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Technological advancements in manufacturing vectors
3.4.2. Robust pipelines for gene therapies and vaccines
3.4.3. Increasing number of emerging players
3.5. Market Restraint Analysis
3.5.1. Regulatory, scientific and ethical challenges
3.5.2. Production capacity challenges
3.6. Penetration and Growth Prospect Mapping 2022
3.7. Business Environment Analysis
3.7.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.7.2. Porter’s Five Forces Analysis
3.8. COVID-19 Impact Analysis
Chapter 4. Scale Of Operations Business Analysis
4.1. Adeno Associated Virus Vector Manufacturing Market: Scale Of Operations Movement Analysis
4.2. Clinical
4.2.1. Clinical Market, 2018 – 2030 (USD Million)
4.3. Preclinical
4.3.1. Preclinical Market, 2018 – 2030 (USD Million)
4.4. Commercial
4.4.1. Commercial Market, 2018 – 2030 (USD Million)
Chapter 5. Method Business Analysis
5.1. Adeno Associated Virus Vector Manufacturing Market: Method Movement Analysis
5.2. In Vitro
5.2.1. In vitro Market, 2018 – 2030 (USD Million)
5.3. In Vivo
5.3.1. In vivo Market, 2018 – 2030 (USD Million)
Chapter 6. Therapeutic Area Business Analysis
6.1. Adeno Associated Virus Vector Manufacturing Market: Therapeutic Area Movement Analysis
6.2. Hematological Diseases
6.2.1. Hematological Diseases Market, 2018 – 2030 (USD Million)
6.3. Infectious Diseases
6.3.1. Infectious Diseases Market, 2018 – 2030 (USD Million)
6.4. Genetic Disorders
6.4.1. Genetic Disorders Market, 2018 – 2030 (USD Million)
6.5. Neurological Disorders
6.5.1. Neurological Disorders Market, 2018 – 2030 (USD Million)
6.6. Ophthalmic Disorders
6.6.1. Ophthalmic Disorders Market, 2018 – 2030 (USD Million)
6.7. Others
6.7.1. Orders Market, 2018 – 2030 (USD Million)
Chapter 7. Application Business Analysis
7.1. Adeno Associated Virus Vector Manufacturing Market: Application Movement Analysis
7.2. Cell Therapy
7.2.1. Cell Therapy Market, 2018 – 2030 (USD Million)
7.3. Gene Therapy
7.3.1. Gene Therapy Market, 2018 – 2030 (USD Million)
7.4. CRO
7.4.1. CRO Market, 2018 – 2030 (USD Million)
7.5. Vaccine
7.5.1. Vaccine Market, 2018 – 2030 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Adeno Associated Virus Vector Manufacturing Market Share By Region, 2022 & 2030
8.2. North America
8.2.1. SWOT Analysis
8.2.2. North America adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.2.3. U.S.
8.2.3.1. Key Country Dynamics
8.2.3.2. Target Disease Prevalence
8.2.3.3. Competitive Scenario
8.2.3.4. Regulatory Framework
8.2.3.5. U.S. adeno associated virus vector manufacturing market, 2018 – 2030 (USD MILLION)
8.2.4. Canada
8.2.4.1. Key Country Dynamics
8.2.4.2. Target Disease Prevalence
8.2.4.3. Competitive Scenario
8.2.4.4. Regulatory Framework
8.2.4.5. Canada adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.3. Europe
8.3.1. SWOT Analysis
8.3.2. Europe adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.3.3. Germany
8.3.3.1. Key Country Dynamics
8.3.3.2. Target Disease Prevalence
8.3.3.3. Competitive Scenario
8.3.3.4. Regulatory Framework
8.3.3.5. Germany adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.3.4. U.K.
8.3.4.1. Key Country Dynamics
8.3.4.2. Target Disease Prevalence
8.3.4.3. Competitive Scenario
8.3.4.4. Regulatory Framework
8.3.4.5. U.K. adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.3.5. France
8.3.5.1. Key Country Dynamics
8.3.5.2. Target Disease Prevalence
8.3.5.3. Competitive Scenario
8.3.5.4. Regulatory Framework
8.3.5.5. France adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.3.6. Italy
8.3.6.1. Key Country Dynamics
8.3.6.2. Target Disease Prevalence
8.3.6.3. Competitive Scenario
8.3.6.4. Regulatory Framework
8.3.6.5. Italy adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.3.7. Spain
8.3.7.1. Key Country Dynamics
8.3.7.2. Target Disease Prevalence
8.3.7.3. Competitive Scenario
8.3.7.4. Regulatory Framework
8.3.7.5. Spain adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.3.8. Denmark
8.3.8.1. Key Country Dynamics
8.3.8.2. Target Disease Prevalence
8.3.8.3. Competitive Scenario
8.3.8.4. Regulatory Framework
8.3.8.5. Denmark adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.3.9. Sweden
8.3.9.1. Key Country Dynamics
8.3.9.2. Target Disease Prevalence
8.3.9.3. Competitive Scenario
8.3.9.4. Regulatory Framework
8.3.9.5. Sweden adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.3.10. Norway
8.3.10.1. Key Country Dynamics
8.3.10.2. Target Disease Prevalence
8.3.10.3. Competitive Scenario
8.3.10.4. Regulatory Framework
8.3.10.5. Norway adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.4. Asia Pacific
8.4.1. SWOT Analysis
8.4.2. Asia Pacific adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.4.3. Japan
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Competitive Scenario
8.4.3.4. Regulatory Framework
8.4.3.5. Japan adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.4.4. China
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Competitive Scenario
8.4.4.4. Regulatory Framework
8.4.4.5. China adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.4.5. India
8.4.5.1. Key Country Dynamics
8.4.5.2. Target Disease Prevalence
8.4.5.3. Competitive Scenario
8.4.5.4. Regulatory Framework
8.4.5.5. India adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.4.6. South Korea
8.4.6.1. Key Country Dynamics
8.4.6.3. Competitive Scenario
8.4.6.4. Regulatory Framework
8.4.6.5. South Korea adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.4.7. Australia
8.4.7.1. Key Country Dynamics
8.4.7.2. Target Disease Prevalence
8.4.7.3. Competitive Scenario
8.4.7.4. Regulatory Framework
8.4.7.5. Australia adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.4.8. Thailand
8.4.8.1. Key Country Dynamics
8.4.8.2. Target Disease Prevalence
8.4.8.3. Competitive Scenario
8.4.8.4. Regulatory Framework
8.4.8.5. Thailand adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.5. Latin America
8.5.1. SWOT Analysis
8.5.2. Latin America adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.5.3. Brazil
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Competitive Scenario
8.5.3.4. Regulatory Framework
8.5.3.5. Brazil adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.5.4. Mexico
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Competitive Scenario
8.5.4.4. Regulatory Framework
8.5.4.5. Mexico adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.5.5. Argentina
8.5.5.1. Key Country Dynamics
8.5.5.2. Target Disease Prevalence
8.5.5.3. Competitive Scenario
8.5.5.4. Regulatory Framework
8.5.5.5. Argentina adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.6. MEA
8.6.1. SWOT Analysis
8.6.2. MEA adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.6.3. South Africa
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Competitive Scenario
8.6.3.4. Regulatory Framework
8.6.3.5. South Africa adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.6.4. Saudi Arabia
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Competitive Scenario
8.6.4.4. Regulatory Framework
8.6.4.5. Saudi Arabia adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.6.5. UAE
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Competitive Scenario
8.6.5.4. Regulatory Framework
8.6.5.5. UAE adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
8.6.6. Kuwait
8.6.6.1. Key Country Dynamics
8.6.6.2. Target Disease Prevalence
8.6.6.3. Competitive Scenario
8.6.6.4. Regulatory Framework
8.6.6.5. Kuwait adeno associated virus vector manufacturing market, 2018 – 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant’s overview
9.1.1. Roche
9.1.2. Biomarin Pharmaceutical
9.1.3. Oxford BioMedica
9.1.4. WuXi AppTec
9.1.5. YPOSKESI
9.1.6. Sarepta Therapeutics
9.1.7. Pfizer
9.1.8. Audentes Therapeutics
9.2. Financial performance
9.3. Participant categorization
9.3.1. Market Leaders
9.3.2. Adeno associated virus vector manufacturing market Share Analysis, 2022
9.3.3. Strategy Mapping
9.3.3.1. Expansion
9.3.3.2. Acquisition
9.3.3.3. Collaborations
9.3.3.4. Product/Therapeutic Area Launch
9.3.3.5. Partnerships
9.3.3.6. Others
|
| ※본 조사보고서 [세계의 아데노 수반 바이러스 벡터 제조 시장 (2023~2030) : 임상, 상업] (코드 : GRV23MR008) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 아데노 수반 바이러스 벡터 제조 시장 (2023~2030) : 임상, 상업] 에 대해서 E메일 문의는 여기를 클릭하세요. |
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!
